Results 161 to 170 of about 30,754 (261)

Hippo Pathway–YAP/TAZ Signaling: Molecular Mechanisms, Biological Function, Diseases, and Therapeutic Targets

open access: yesMedComm, Volume 7, Issue 10, October 2026.
The Hippo–YAP/TAZ–TEAD pathway integrates mechanical and biochemical cues to govern organ growth, regeneration, cancer, and fibrosis. This review dissects pathway physiology, TEAD structural pharmacology and ligandable pockets, and therapeutic strategies spanning palmitoylation‐pocket inhibitors, PROTAC degraders, and gene/RNA therapies, highlighting ...
Xiaodan Qu, Zhan‐you Wang
wiley   +1 more source

The role of macrophage migration inhibitory factor (MIF) in the pathogenesis and progression of cardiovascular disease

open access: yesBritish Journal of Pharmacology, Volume 183, Issue 19, Page 5732-5751, October 2026.
Abstract Cardiovascular disease (CVD) remains the leading global cause of death, driven by complex mechanisms, in which chronic inflammation plays a central role. Inflammatory pathways contribute to all stages of CVD, from endothelial dysfunction and plaque formation to erosion, rupture and myocardial injury.
Shreya Mahabhashyam   +4 more
wiley   +1 more source

Cardiovascular Autonomic Neuropathy and Indices of Heart Failure in Type 2 Diabetes: The CANCAN Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9356-9366, October 2026.
ABSTRACT Aim To quantify the association between cardiovascular autonomic neuropathy (CAN) and heart failure (HF) in individuals with type 2 diabetes (T2D). Materials and Methods Two hundred T2D individuals were recruited from two Danish outpatient clinics between 2021–2024. CAN was defined by abnormal cardiovascular autonomic reflex test results.
Jonas R. Schaarup   +7 more
wiley   +1 more source

HFpEF-ABA Score for the Diagnosis and Prognosis of HFpEF in Outpatients With Type 2 Diabetes. [PDF]

open access: yesJACC Adv
Gonzalez-Manzanares R   +7 more
europepmc   +1 more source

Glycemic and Renal Effects of SGLT2 Inhibitors in Monogenic Diabetes: A Real‐World National Study

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9633-9643, October 2026.
ABSTRACT Aims Evidence regarding the efficacy and safety of sodium–glucose cotransporter 2 inhibitors (SGLT2i) in monogenic diabetes is limited. We evaluated real‐world metabolic, renal, and safety outcomes of SGLT2i therapy in adults with monogenic diabetes.
Estelle Audrain   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy